세계의 녹내장 시장 : 규모, 점유율, 성장 분석, 유형별, 약제 클래스별, 투여법별, 최종 용도별, 유통별, 지역별 산업 예측(2024-2031년)
Glaucoma Market Size, Share, Growth Analysis, By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG)), By Drug Class (Beta Blockers, Prostaglandins), By Administration, By End Use, By Distribution, By Region - Industry Forecast 2024-2031
상품코드:1619083
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2024년 12월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
녹내장 세계 시장 규모는 2022년 81억 달러로 평가되었고, 2023년 86억 3,000만 달러에서 2031년에는 144억 달러로 성장해 예측기간(2024-2031년)의 CAGR은 6.6%로 나타날 전망입니다.
세계의 녹내장 시장은 일관된 성장을 이루고 있으며, 특히 고령화 사회와 만성 안 질환을 가진 사람들 사이에서 이 만성 안 질환의 유병률이 상승하고 있는 것이 주요 요인 되어 있습니다. 레이저 치료 등의 진단·치료 기술의 진보가 시장 확대를 더욱 뒷받침하고 있습니다. 경쟁 구도은 주요 업계 기업의 활발한 활동에 의해 특징지어져 혁신적인 정세 관리 솔루션의 지속적인 연구 개발을 뒷받침하고 있습니다. 개선이 진행됨에 따라 세계 녹내장 시장은 향후 수년간 안정적으로 성장할 것으로 예상되며, 이 중대한 건강 문제에 대한 노력의 중요성이 강조되고 있습니다.
목차
소개
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터의 방법
시장 규모 예측
시장의 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
억제요인과 과제
Porter's Five Forces 분석
주요 시장 인사이트
중요성공요인
경쟁도
주요 투자 기회
시장 생태계
시장의 매력 지수(2023년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
녹내장 시장 규모 : 유형별 및 CAGR(2024-2031년)
시장 개요
폐쇄각 녹내장(CAG)
개방각 녹내장(OAG)
속발 녹내장
선천성 녹내장
기타
녹내장 시장 규모 : 약제 클래스별 및 CAGR(2024-2031년)
시장 개요
베타 차단제
프로스타글란딘
알파 아드레날린 작용제
탄산탈수효소 억제제
병용약
기타
녹내장 시장 규모 : 투여법별 및 CAGR(2024-2031년)
시장 개요
경구
주사
유리체내
기타
녹내장 시장 규모 : 최종 용도별 및 CAGR(2024-2031년)
시장 개요
병원
전문센터
기타
녹내장 시장 규모 : 유통별 및 CAGR(2024-2031년)
시장 개요
병원
온라인
소매
녹내장 시장 규모 및 CAGR(2024-2031년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 정보
상위 5개사 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2023년)
주요 기업의 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2021-2023년)
주요 기업 프로파일
Aerie Pharmaceuticals(USA)
Akorn, Inc.(USA)
AbbVie Inc.(USA)
Bausch Health Companies Inc.(Canada)
Inotek Pharmaceuticals Corp.(USA)
Merck & Co., Inc.(USA)
Novartis AG(Switzerland)
Pfizer Inc.(USA)
Santen Pharmaceutical Co., Ltd.(Japan)
Glaukos Corporation(USA)
Ocular Therapeutix, Inc.(USA)
Santen Inc.(Japan)
Ono Pharmaceutical Co., Ltd.(Japan)
Nicox SA(France)
Sun Pharmaceutical Industries Ltd.(India)
Visiox Pharma(USA)
TearClear(USA)
MediPrint Ophthalmics(formerly Leo Lens Pharma)(Denmark)
Tarsier Pharma(USA)
Peregrine Ophthalmic(USA)
결론과 권장사항
JHS
영문 목차
영문목차
Global Glaucoma Market size was valued at USD 8.1 billion in 2022 and is poised to grow from USD 8.63 billion in 2023 to USD 14.4 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).
The global glaucoma market is experiencing consistent growth, primarily fueled by the rising prevalence of this chronic eye condition, particularly among the aging population and those with chronic eye diseases. Advancements in diagnostic and treatment technologies, including minimally invasive surgeries and laser therapies, further bolster market expansion. However, challenges such as high treatment costs and limited healthcare access in certain areas pose obstacles to growth. The competitive landscape is marked by significant activity among key industry players, driving continuous research and development for innovative glaucoma management solutions. As awareness, early detection, and improved treatment options progress, the global glaucoma market is anticipated to grow steadily in the coming years, underscoring the importance of addressing this critical health issue.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glaucoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Glaucoma Market Segmental Analysis
Global Glaucoma Market is segmented by type, drug class, administration, end use, distribution and region. Based on type, the market is segmented into closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others. Based on drug class, the market is segmented into beta blockers, prostaglandins, alpha adrenergic agonist, carbonic anhydrase inhibitors, combination drugs and others. Based on administration, the market is segmented into oral, injections, intravitreal and other. Based on end use, the market is segmented into hospitals, specialty centers and others. Based on distribution, the market is segmented into hospital, online and retail. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Glaucoma Market
A significant impetus for the global glaucoma market stems from the escalating prevalence of the condition across the globe. This surge is primarily driven by an aging population and a rise in chronic illnesses, including diabetes and hypertension, which heighten the likelihood of glaucoma development. Given that glaucoma is a major contributor to irreversible blindness, there is an urgent requirement for early detection, diagnosis, and treatment options. Consequently, this situation stimulates demand for cutting-edge glaucoma management solutions, encompassing advanced diagnostic equipment, effective medications, and surgical treatments, all aimed at improving patient outcomes and reducing the risk of vision loss.
Restraints in the Global Glaucoma Market
The global glaucoma market faces significant restraints primarily due to limited awareness and inadequate routine screening practices for this condition in various regions. As glaucoma often presents asymptomatically in its early stages, the absence of regular eye exams complicates timely diagnosis. This lack of awareness among both the general public and healthcare providers can result in late-stage diagnosis and subsequent irreversible vision loss. Additionally, the high costs associated with managing glaucoma-encompassing medications, surgical interventions, and long-term care-pose substantial barriers to access, particularly for patients in low- and middle-income countries, further exacerbating the challenges in glaucoma management and treatment.
Market Trends of the Global Glaucoma Market
The global glaucoma market is witnessing a significant trend towards the adoption of advanced diagnostic technologies and innovative treatment modalities, driven by the urgent need for early detection and management of this potentially debilitating eye disease. As awareness increases regarding the irreversible vision loss associated with glaucoma, healthcare providers are prioritizing regular screenings and advanced imaging techniques for timely diagnosis. Technologies like optical coherence tomography (OCT), visual field testing, and advanced tonometry are increasingly utilized to enhance diagnostic accuracy and patient monitoring. This trend is fostering a robust market environment, as both established and emerging players invest in cutting-edge solutions to better address patient needs and optimize treatment outcomes.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Glaucoma Market Size by Type & CAGR (2024-2031)
Market Overview
Closed Angle Glaucoma (CAG)
Open Angle Glaucoma (OAG)
Secondary Glaucoma
Congenital Glaucoma
Others
Global Glaucoma Market Size by Drug Class & CAGR (2024-2031)
Market Overview
Beta Blockers
Prostaglandins
Alpha Adrenergic Agonist
Carbonic Anhydrase Inhibitors
Combination Drugs
Others
Global Glaucoma Market Size by Administration & CAGR (2024-2031)
Market Overview
Oral
Injections
Intravitreal
Other
Global Glaucoma Market Size by End Use & CAGR (2024-2031)
Market Overview
Hospitals
Specialty Centers
Others
Global Glaucoma Market Size by Distribution & CAGR (2024-2031)
Market Overview
Hospital
Online
Retail
Global Glaucoma Market Size & CAGR (2024-2031)
North America (Type, Drug Class, Administration, End Use, Distribution)
US
Canada
Europe (Type, Drug Class, Administration, End Use, Distribution)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Drug Class, Administration, End Use, Distribution)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Drug Class, Administration, End Use, Distribution)
Brazil
Rest of Latin America
Middle East & Africa (Type, Drug Class, Administration, End Use, Distribution)
GCC Countries
South Africa
Rest of Middle East & Africa
Competitive Intelligence
Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
Company Details
Product Portfolio Analysis
Company's Segmental Share Analysis
Revenue Y-O-Y Comparison (2021-2023)
Key Company Profiles
Aerie Pharmaceuticals (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Akorn, Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
AbbVie Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Bausch Health Companies Inc. (Canada)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Inotek Pharmaceuticals Corp. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Merck & Co., Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Pfizer Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Glaukos Corporation (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Ocular Therapeutix, Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Santen Inc. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Ono Pharmaceutical Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Nicox S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Sun Pharmaceutical Industries Ltd. (India)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Visiox Pharma (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
TearClear (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
MediPrint Ophthalmics (formerly Leo Lens Pharma) (Denmark)
